| Vertex reports 3Q loss | |
| | |
|
BOSTON (AP) -- Vertex Pharmaceuticals Inc. (VRTX) on Wednesday reported a loss of $95.1 million in its third quarter.
On a per-share basis, the Boston-based company said it had a loss of 39 cents. Losses, adjusted for one-time gains and costs, were 13 cents per share.
The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 28 cents per share.
The drugmaker posted revenue of $309.8 million in the period, which also topped Street forecasts. Seven analysts surveyed by Zacks expected $231.3 million.
Vertex shares have increased 1 percent since the beginning of the year, while the Standard & Poor's 500 index has increased 1.5 percent. Its shares closed Wednesday at 120.10, a rise of 5.3 percent in the last 12 months.
_____
Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VRTX at http://www.zacks.com/ap/VRTX
_____
Keywords: Vertex Pharmaceuticals, Earnings Report
|
|
| |
ProfilIndicateurs de MarchéVALEUR : Projets & res.Communiqués de PresseRapport annuelRISQUE : Profile actifsContactez la cie |
Vertex Pharma est une société basée aux Etats-Unis D'Amerique. Vertex Pharma est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 99,9 milliards US$ (92,8 milliards €). La valeur de son action a atteint son plus bas niveau récent le 12 mars 2004 à 10,00 US$, et son plus haut niveau récent le 03 mai 2024 à 401,08 US$. Vertex Pharma possède 249 070 000 actions en circulation. |